Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 368,394
  • Shares Outstanding, K 223,269
  • Annual Sales, $ 0 K
  • Annual Income, $ -283,260 K
  • EBIT $ -312 M
  • EBITDA $ -288 M
  • 60-Month Beta 1.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.22

Options Overview Details

View History
  • Implied Volatility 629.38% ( +268.53%)
  • Historical Volatility 106.45%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 629.38% on 12/20/24
  • IV Low 67.95% on 10/07/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 142
  • Volume Avg (30-Day) 345
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 34,426
  • Open Int (30-Day) 32,670

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.31
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5500 +6.45%
on 12/20/24
3.0700 -46.25%
on 12/02/24
-0.8800 (-34.78%)
since 11/20/24
3-Month
1.5500 +6.45%
on 12/20/24
4.4450 -62.88%
on 09/27/24
-2.6000 (-61.18%)
since 09/20/24
52-Week
1.5500 +6.45%
on 12/20/24
12.0000 -86.25%
on 03/01/24
-2.4500 (-59.76%)
since 12/20/23

Most Recent Stories

More News
Sana Biotechnology Receives FDA Fast Track Designation for SC291 in Treatment of Relapsed/Refractory Systemic Lupus Erythematosus

Sana Biotechnology's SC291 receives FDA Fast Track designation for treating relapsed/refractory systemic lupus erythematosus, with initial data expected in 2025.Quiver AI SummarySana Biotechnology, Inc....

SANA : 1.6500 (+3.12%)
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus

SANA : 1.6500 (+3.12%)
Sana Biotechnology to Present at December 2024 Investor Conferences

SANA : 1.6500 (+3.12%)
Sana: Q3 Earnings Snapshot

Sana: Q3 Earnings Snapshot

SANA : 1.6500 (+3.12%)
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

SANA : 1.6500 (+3.12%)
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

SANA : 1.6500 (+3.12%)
Sana: Q2 Earnings Snapshot

Sana: Q2 Earnings Snapshot

SANA : 1.6500 (+3.12%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 21.45 (-0.19%)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 1.9000
2nd Resistance Point 1.8100
1st Resistance Point 1.7300
Last Price 1.6500
1st Support Level 1.5600
2nd Support Level 1.4700
3rd Support Level 1.3900

See More

52-Week High 12.0000
Fibonacci 61.8% 8.0081
Fibonacci 50% 6.7750
Fibonacci 38.2% 5.5419
Last Price 1.6500
52-Week Low 1.5500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar